Search

Your search keyword '"Bomback, Andrew"' showing total 772 results

Search Constraints

Start Over You searched for: Author "Bomback, Andrew" Remove constraint Author: "Bomback, Andrew"
772 results on '"Bomback, Andrew"'

Search Results

2. Safety and Efficacy of Avacopan in Patients with Complement 3 Glomerulopathy: Randomized, Double-Blind Clinical Trial

3. Natural History and Clinicopathological Associations of TRPC6-Associated Podocytopathy

7. Increased risk of kidney failure in patients with genetic kidney disorders

8. C3 Glomerulopathy Recurs Early after Kidney Transplantation in Serial Biopsies Performed within the First Two Years Post-Transplantation

9. DEVELOPING THERAPIES FOR C3G: REPORT OF THE KIDNEY HEALTH INITIATIVE C3G TRIAL ENDPOINTS WORK GROUP

10. Real-World Experience With Avacopan in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis

12. Rationale and design of the Kidney Precision Medicine Project

13. Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy

15. Precision Medicine in Nephrology: An Integrative Framework of Multidimensional Data in the Kidney Precision Medicine Project

17. Association of COVID-19 Versus COVID-19 Vaccination With Kidney Function and Disease Activity in Primary Glomerular Disease: A Report of the Cure Glomerulonephropathy Study

18. The Significance of Hematuria in Podocytopathies

19. Urinary EGF and MCP-1 and risk of CKD after cardiac surgery.

20. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

21. Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease

22. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial

23. Implementation and Feasibility of Clinical Genome Sequencing Embedded Into the Outpatient Nephrology Care for Patients With Proteinuric Kidney Disease

24. Molecular Signatures of Glomerular Neovascularization in a Patient with Diabetic Kidney Disease

25. Participant Experience with Protocol Research Kidney Biopsies in the Kidney Precision Medicine Project

26. Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulonephropathy Network

27. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

28. Racial and Ethnic Disparities in Acute Care Utilization Among Patients With Glomerular Disease

31. A Participant-Centered Approach to Understanding Risks and Benefits of Participation in Research Informed by the Kidney Precision Medicine Project

32. Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

34. Rare Single Nucleotide and Copy Number Variants and the Etiology of Congenital Obstructive Uropathy: Implications for Genetic Diagnosis

35. Cadherin-11, Sparc-related modular calcium binding protein-2, and Pigment epithelium-derived factor are promising non-invasive biomarkers of kidney fibrosis

39. Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study

40. Association of HLA Typing and Alloimmunity With Posttransplantation Membranous Nephropathy: A Multicenter Case Series

41. Persistent Disease Activity in Patients With Long-Standing Glomerular Disease

45. Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations

46. #1467 Pegcetacoplan for post-transplant recurrent C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis in NOBLE: 12-week evolution

48. Factor B Inhibition with Iptacopan in Recurrent C3 Glomerulopathy Following Kidney Transplant: A Report of Two Cases

49. WCN24-683 EFFICACY OF 12-WEEK PEGCETACOPLAN IN KIDNEY TRANSPLANT RECIPIENTS WITH RECURRENT C3 GLOMERULOPATHY (C3G) OR IMMUNE COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN)

Catalog

Books, media, physical & digital resources